FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911330121> ?p ?o ?g. }

• W2911330121 endingPage "A024" @default.
• W2911330121 startingPage "A024" @default.
• W2911330121 abstract "Abstract Based on the hypothesis that early use of androgen deprivation therapy (ADT) may improve outcomes, we conducted a phase 2 trial of neoadjuvant leuprolide for 24 weeks in combination with abiraterone acetate plus prednisone (referred to subsequently as leuprolide plus AAP) for 12 or 24 weeks prior to radical prostatectomy (RP). As reported recently, we confirmed that the addition of AAP further markedly reduced intraprostatic androgen levels and appeared to improve responses relative to historical controls using single-agent GnRH agonists. Nonetheless, residual prostate cancer (PCa) was found in the majority of patients, with only a small number of patients demonstrating complete pathologic responses. Moreover, substantial nuclear and cytoplasmic AR expression was detected by immunohistochemistry in most cases, suggesting that AR activity still may persist and contribute to residual disease. Residual PCa foci in RPs from 18 men treated with neoadjuvant intensive androgen deprivation therapy (leuprolide plus AAP) were microdissected and analyzed for resistance mechanisms. Transcriptome profiling showed reduced but persistent androgen receptor (AR) activity in residual tumors, with no increase in neuroendocrine differentiation. Unexpectedly, proliferation was negatively correlated with AR activity, but positively correlated with decreased RB1 expression, and whole-exome sequencing (WES) further showed enrichment for RB1 genomic loss. In 14 cases where two tumor foci were microdissected, WES confirmed a common origin, but identified multiple oncogenic alterations unique to one focus. Primary PCa can have extensive microheterogeneity, but its contribution to the later emergence of metastatic castration-resistant PCa (mCRPC) has not been clear. These findings indicate that neoadjuvant intense androgen deprivation therapy selects for subclonal genomic alterations, including RB1 loss, which may be the origin for metastatic castration-resistant PCa. This study indicates that subclonal RB1 loss may be more common than previously appreciated in intermediate- to high-risk primary PCa, and may be an early event, independent of neuroendocrine differentiation, in the development of mCRPC. Comprehensive molecular analyses of primary PCa may detect aggressive subclones, and possibly inform on adjuvant strategies to prevent the emergence of mCRPC. Citation Format: Adam G. Sowalsky, Huihui Ye, Manoj Bhasin, Eliezer M. Van Allen, Massimo Loda, Rosina T. Lis, Laleh Montaser, Carla Calagua, Fen Ma, Joshua W. Russo, Rachel J. Schaefer, Olga S. Voznesensky, Zhenwei Zhang, Glenn J. Bubley, Robert B. Montgomery, Elahe A. Mostaghel, Peter S. Nelson, Mary-Ellen Taplin, Steven P. Balk. Prostate cancer neoadjuvant intensive androgen deprivation therapy selects for tumor foci with diverse oncogenic alterations [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A024." @default.
• W2911330121 created "2019-02-21" @default.
• W2911330121 creator A5002712288 @default.
• W2911330121 creator A5017926102 @default.
• W2911330121 creator A5023418980 @default.
• W2911330121 creator A5023517416 @default.
• W2911330121 creator A5037614901 @default.
• W2911330121 creator A5039044023 @default.
• W2911330121 creator A5039452787 @default.
• W2911330121 creator A5043769628 @default.
• W2911330121 creator A5047770287 @default.
• W2911330121 creator A5051660049 @default.
• W2911330121 creator A5056157924 @default.
• W2911330121 creator A5058656563 @default.
• W2911330121 creator A5067800417 @default.
• W2911330121 creator A5068667672 @default.
• W2911330121 creator A5070846601 @default.
• W2911330121 creator A5071509387 @default.
• W2911330121 creator A5071763026 @default.
• W2911330121 creator A5073144121 @default.
• W2911330121 creator A5087350413 @default.
• W2911330121 date "2018-08-14" @default.
• W2911330121 modified "2023-10-14" @default.
• W2911330121 title "Abstract A024: Prostate cancer neoadjuvant intensive androgen deprivation therapy selects for tumor foci with diverse oncogenic alterations" @default.
• W2911330121 doi "https://doi.org/10.1158/1538-7445.prca2017-a024" @default.
• W2911330121 hasPublicationYear "2018" @default.
• W2911330121 type Work @default.
• W2911330121 sameAs 2911330121 @default.
• W2911330121 citedByCount "0" @default.
• W2911330121 crossrefType "journal-article" @default.
• W2911330121 hasAuthorship W2911330121A5002712288 @default.
• W2911330121 hasAuthorship W2911330121A5017926102 @default.
• W2911330121 hasAuthorship W2911330121A5023418980 @default.
• W2911330121 hasAuthorship W2911330121A5023517416 @default.
• W2911330121 hasAuthorship W2911330121A5037614901 @default.
• W2911330121 hasAuthorship W2911330121A5039044023 @default.
• W2911330121 hasAuthorship W2911330121A5039452787 @default.
• W2911330121 hasAuthorship W2911330121A5043769628 @default.
• W2911330121 hasAuthorship W2911330121A5047770287 @default.
• W2911330121 hasAuthorship W2911330121A5051660049 @default.
• W2911330121 hasAuthorship W2911330121A5056157924 @default.
• W2911330121 hasAuthorship W2911330121A5058656563 @default.
• W2911330121 hasAuthorship W2911330121A5067800417 @default.
• W2911330121 hasAuthorship W2911330121A5068667672 @default.
• W2911330121 hasAuthorship W2911330121A5070846601 @default.
• W2911330121 hasAuthorship W2911330121A5071509387 @default.
• W2911330121 hasAuthorship W2911330121A5071763026 @default.
• W2911330121 hasAuthorship W2911330121A5073144121 @default.
• W2911330121 hasAuthorship W2911330121A5087350413 @default.
• W2911330121 hasConcept C121608353 @default.
• W2911330121 hasConcept C126322002 @default.
• W2911330121 hasConcept C134018914 @default.
• W2911330121 hasConcept C143998085 @default.
• W2911330121 hasConcept C204232928 @default.
• W2911330121 hasConcept C2776235491 @default.
• W2911330121 hasConcept C2777899217 @default.
• W2911330121 hasConcept C2777911890 @default.
• W2911330121 hasConcept C2778292576 @default.
• W2911330121 hasConcept C2779466945 @default.
• W2911330121 hasConcept C2780192828 @default.
• W2911330121 hasConcept C502942594 @default.
• W2911330121 hasConcept C530470458 @default.
• W2911330121 hasConcept C61367390 @default.
• W2911330121 hasConcept C71315377 @default.
• W2911330121 hasConcept C71924100 @default.
• W2911330121 hasConceptScore W2911330121C121608353 @default.
• W2911330121 hasConceptScore W2911330121C126322002 @default.
• W2911330121 hasConceptScore W2911330121C134018914 @default.
• W2911330121 hasConceptScore W2911330121C143998085 @default.
• W2911330121 hasConceptScore W2911330121C204232928 @default.
• W2911330121 hasConceptScore W2911330121C2776235491 @default.
• W2911330121 hasConceptScore W2911330121C2777899217 @default.
• W2911330121 hasConceptScore W2911330121C2777911890 @default.
• W2911330121 hasConceptScore W2911330121C2778292576 @default.
• W2911330121 hasConceptScore W2911330121C2779466945 @default.
• W2911330121 hasConceptScore W2911330121C2780192828 @default.
• W2911330121 hasConceptScore W2911330121C502942594 @default.
• W2911330121 hasConceptScore W2911330121C530470458 @default.
• W2911330121 hasConceptScore W2911330121C61367390 @default.
• W2911330121 hasConceptScore W2911330121C71315377 @default.
• W2911330121 hasConceptScore W2911330121C71924100 @default.
• W2911330121 hasIssue "16_Supplement" @default.
• W2911330121 hasLocation W29113301211 @default.
• W2911330121 hasOpenAccess W2911330121 @default.
• W2911330121 hasPrimaryLocation W29113301211 @default.
• W2911330121 hasRelatedWork W2004261902 @default.
• W2911330121 hasRelatedWork W2005958584 @default.
• W2911330121 hasRelatedWork W2040706884 @default.
• W2911330121 hasRelatedWork W2103250319 @default.
• W2911330121 hasRelatedWork W2140855177 @default.
• W2911330121 hasRelatedWork W2154368013 @default.
• W2911330121 hasRelatedWork W2322485784 @default.
• W2911330121 hasRelatedWork W2361362907 @default.
• W2911330121 hasRelatedWork W2412061698 @default.
• W2911330121 hasRelatedWork W2600102258 @default.
• W2911330121 hasVolume "78" @default.
• W2911330121 isParatext "false" @default.
• W2911330121 isRetracted "false" @default.

• next